Compare ProShares UltraPro Short QQQ ETF (SQQQ) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraPro Short QQQ ETF vs 10X Genomics Inc — how do they compare? ProShares UltraPro Short QQQ ETF trades at $32.91 (market cap $2.23B), while 10X Genomics Inc trades at $81 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 4.5× ProShares UltraPro Short QQQ ETF's market cap, and 10X Genomics Inc is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraPro Short QQQ ETF for 12 Days and 10X Genomics Inc for 91 Days on average.
| SQQQ | TXG | |
|---|---|---|
Market Cap | $2.23B | $10.07B |
Volume | 60,436,012 | 5,657,286 |
Sector | Leveraged / Inverse | Health |
52-Week High | $89.43 | $97.74 |
52-Week Low | $31.83 | $11.48 |
Typical Hold Time | 12 Days | 91 Days |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SQQQ trades at $32.95, up 2.71% with a bearish technical signal from moving averages while oscillators remain neutral. The ETF shows no traditional financial ratios as it's an inverse leveraged product designed to move opposite the Nasdaq 100. Recent news highlights its role as a hedging tool against tech sector declines, with articles discussing strategic pairing with QQQ positions.
As a 3x leveraged inverse ETF, SQQQ carries significant risk from daily rebalancing and decay. It serves as a tactical tool for bearish Nasdaq 100 views or portfolio hedging, but requires active management. The primary risk remains volatility decay and timing sensitivity in a market where tech stocks have shown long-term growth trends.
TXG trades at $80.65, up 5.98% on the day, showing strong recent momentum despite a bearish technical signal. The company reported revenue of $642.82M for 2025 with a gross margin of 70.03%, but remains unprofitable with a net loss of $43.54M. Recent news highlights the launch of the Atera spatial biology platform and a patent victory, signaling innovation and competitive strength. Analyst consensus is mixed with a $74.30 price target below the current price, indicating caution on valuation.
The outlook for TXG hinges on commercial execution of new products like Atera to drive revenue growth and a path to profitability. Investment opportunity lies in its leading technology platform and expanding market demand in genomics. Key risks include persistent losses, high valuation multiples, and competitive pressures in the life sciences tools sector. The stock's recent rally faces a test near technical resistance at $81.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
